Evernest Financial Advisors LLC Has $1.18 Million Holdings in Stryker Co. (NYSE:SYK)

Evernest Financial Advisors LLC raised its stake in shares of Stryker Co. (NYSE:SYK) by 4.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,271 shares of the medical technology company’s stock after purchasing an additional 139 shares during the quarter. Evernest Financial Advisors LLC’s holdings in Stryker were worth $1,178,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in SYK. Capital Planning LLC raised its holdings in Stryker by 3.6% in the 4th quarter. Capital Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after acquiring an additional 29 shares in the last quarter. Alhambra Investment Management LLC increased its position in shares of Stryker by 1.5% during the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock valued at $719,000 after purchasing an additional 29 shares during the period. Avestar Capital LLC raised its stake in shares of Stryker by 1.1% in the third quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock valued at $1,065,000 after purchasing an additional 31 shares in the last quarter. Union Savings Bank boosted its stake in Stryker by 1.0% during the fourth quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock worth $1,138,000 after buying an additional 31 shares in the last quarter. Finally, Patrick M Sweeney & Associates Inc. increased its holdings in Stryker by 1.5% in the 3rd quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company’s stock valued at $793,000 after buying an additional 32 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 0.2 %

Shares of NYSE:SYK opened at $390.48 on Friday. The company has a 50 day moving average of $376.55 and a 200-day moving average of $362.18. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a market cap of $148.86 billion, a price-to-earnings ratio of 50.32, a P/E/G ratio of 2.68 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.86%. During the same quarter in the previous year, the business posted $3.46 earnings per share. On average, sell-side analysts forecast that Stryker Co. will post 13.53 earnings per share for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Tuesday, December 31st. Stryker’s payout ratio is presently 43.30%.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of analyst reports. Stifel Nicolaus raised their price objective on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday. Evercore ISI lifted their price objective on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Wells Fargo & Company upped their price objective on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research note on Wednesday. BTIG Research raised their target price on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Citigroup increased their price objective on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $416.40.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.